Pharmacokinetic Interactions with RifampicinClinical Relevance

被引：0
|
作者：
Mikko Niemi
Janne T. Backman
Martin F. Fromm
Pertti J. Neuvonen
Kari T. Kivistö
机构：
[1] University of Helsinki and Helsinki University Central Hospital,Department of Clinical Pharmacology
[2] Dr Margarete Fischer-Bosch Institut für Klinische Pharmakologie,undefined
[3] Bosch Institut für Klinische Pharmakologie,undefined
来源：
Clinical Pharmacokinetics | 2003年 / 42卷
关键词：
Verapamil; Rifampicin; Zolpidem; Propafenone; Repaglinide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The antituberculosis drug rifampicin (rifampin) induces a number of drug-metabolising enzymes, having the greatest effects on the expression of cytochrome P450 (CYP) 3A4 in the liver and in the small intestine. In addition, rifampicin induces some drug transporter proteins, such as intestinal and hepatic P-glycoprotein. Full induction of drug-metabolising enzymes is reached in about 1 week after starting rifampicin treatment and the induction dissipates in roughly 2 weeks after discontinuing rifampicin.
引用
收藏
页码：819 / 850
页数：31
相关论文
共 50 条
  • [21] Pharmacokinetic and pharmacodynamic interactions
    Geniaux, Helene
    Picard, Nicolas
    ACTUALITES PHARMACEUTIQUES, 2019, 58 (586): : 52 - 54
  • [22] Pharmacokinetic interactions with thiazolidinediones
    Scheen, Andre J.
    CLINICAL PHARMACOKINETICS, 2007, 46 (01) : 1 - 12
  • [23] Pharmacokinetic changes during pregnancy and their clinical relevance
    Loebstein, R
    Lalkin, A
    Koren, G
    CLINICAL PHARMACOKINETICS, 1997, 33 (05) : 328 - 343
  • [24] Pharmacokinetic Changes During Pregnancy and Their Clinical Relevance
    Ronen Loebstein
    Arieh Lalkin
    Gideon Koren
    Clinical Pharmacokinetics, 1997, 33 : 328 - 343
  • [25] RELEVANCE OF PROTEIN-BINDING FOR PHARMACOKINETIC MODELS
    DAHL, SG
    ACTA PHYSIOLOGICA SCANDINAVICA, 1973, : 25 - 25
  • [26] Pharmacokinetic relevance of glomerular hyperfiltration for drug dosing
    Zoccali, Carmine
    Mallamaci, Francesca
    De Caterina, Raffaele
    CLINICAL KIDNEY JOURNAL, 2023, 16 (10) : 1580 - 1586
  • [27] Pharmacokinetic interactions of dasatinib and docetaxel
    Leveque, Dominique
    LANCET ONCOLOGY, 2014, 15 (02): : E51 - E51
  • [28] Ecstasy: Pharmacodynamic and pharmacokinetic interactions
    Oesterheld, JR
    Armstrong, SC
    Cozza, KL
    PSYCHOSOMATICS, 2004, 45 (01) : 84 - 87
  • [29] PHARMACOKINETIC DRUG-INTERACTIONS
    EICHELBAUM, M
    JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (06): : 469 - 473
  • [30] Pharmacokinetic drug interactions of azoles
    Roger J. M. Brüggemann
    Jan-Willem C. Alffenaar
    Nicole M. A. Blijlevens
    Eliane M. Billaud
    Jos G. W. Kosterink
    Paul E. Verweij
    David M. Burger
    Current Fungal Infection Reports, 2008, 2 (1)
12345